Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91472 | 0.84 | CDK4 (0.46) | HRH4HRH3NPSR1MAPTCYP2C9 | |
| SCHEMBL17700502 | 0.81 | NPSR1 (0.42) | HRH4HRH3NPSR1MAPTCYP2C9 | |
| SCHEMBL16844971 | 0.80 | HRH4 (0.52) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL9169741 | 0.80 | HRH4 (0.52) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL91473 | 0.79 | NPSR1 (0.49) | NPSR1MAPTCYP2C9MAPK1 | |
| SCHEMBL12932877 | 0.77 | HRH4 (0.50) | HRH4HRH3NUDT1MAPT | |
| SCHEMBL12933710 | 0.77 | HRH4 (0.50) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL14004971 | 0.77 | HRH4 (0.50) | HRH4HRH3NUDT1CHRNA7 | |
| SCHEMBL12933372 | 0.76 | KMT2A (0.52) | NUDT1MAPTMAPK1 | |
| SCHEMBL9278638 | 0.76 | ALDH1A1 (0.54) | HRH4HRH3NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | ARES TRADING SA (CH) | 2018-08-02 | — | — | US | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-20160115128-A1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115128-A1 | AROMATIC COMPOUND | GLP1R, GPR119, GPR39 | HRH4 669/4885HRH3 1204/4885NUDT1 2977/4885 |
| US-20180215770-A1 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES | APP, BACE1, PSEN1 | HRH4 1927/4885HRH3 2402/4885NUDT1 2763/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | HRH4 1565/4885HRH3 1439/4885NUDT1 2462/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | HRH4 1927/4885HRH3 2402/4885NUDT1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.